Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12248056 | 1.00 | TSHR (0.43) | TSHRHTTEPHX2GRIN2DGRIN3B | |
| SCHEMBL12226594 | 0.84 | HTT (0.46) | HTTEPHX2ADRB3GAA | |
| SCHEMBL10231087 | 0.84 | HTT (0.46) | HTTEPHX2ADRB3GAA | |
| SCHEMBL21518431 | 0.74 | GRIN2D (0.50) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5504092 | 0.73 | GRIN2D (0.49) | EPHX2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL16063017 | 0.71 | HTT (0.34) | HTTADRB3GAA | |
| SCHEMBL21518364 | 0.71 | ADRB3 (0.41) | HTTEPHX2ADRB3LMNA | |
| SCHEMBL1150594 | 0.70 | TSHR (0.47) | TSHREPHX2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL353997 | 0.69 | ADRB3 (0.39) | HTTEPHX2ADRB3 | |
| SCHEMBL5504913 | 0.68 | ADRB3 (0.38) | HTTEPHX2ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113591-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113591-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | TSHR 4779/4885HTT 10/4885EPHX2 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.